Exploring the roles of SPARC as a proinflammatory factor and its potential as a novel therapeutic target against...

Area of Science:

• Cardiovascular research
• Inflammation biology
• Extracellular matrix proteins

Background:

• Cardiovascular disease (CVD) remains a leading global cause of mortality, with increasing patient numbers.
• Chronic inflammation is a key pathological factor in CVD development and progression.
• The extracellular matrix (ECM) protein, secreted protein acidic and rich in cysteine (SPARC), is implicated in tissue remodeling and inflammation.

Purpose of the Study:

• To review the regulatory and proinflammatory mechanisms of SPARC in cardiovascular disease (CVD), chronic kidney disease (CKD), and cerebrovascular disease.
• To discuss the potential of SPARC as a biomarker for CVD.
• To explore the therapeutic implications of SPARC inhibition for CVD prevention and treatment.

Main Methods:

• Review of existing literature on SPARC's role in inflammatory and cardiovascular conditions.
• Analysis of preclinical animal models demonstrating SPARC's proinflammatory effects.
• Examination of clinical studies correlating SPARC levels with CVD risk factors and inflammatory markers.

Main Results:

• SPARC exhibits a proinflammatory role in various disease models.
• Elevated plasma SPARC levels are associated with hypertension, obesity, and inflammation.
• SPARC deficiency protects against cardiac injury, suggesting detrimental effects in CVD.

Conclusions:

• SPARC plays a significant role in the pathogenesis of CVD and related diseases.
• SPARC presents a potential biomarker for CVD risk assessment.
• Targeting SPARC offers a promising therapeutic avenue for managing cardiovascular and related inflammatory conditions.